Hepatitis C

Showing NaN - NaN of 64

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Cardiovascular Diseases, Hepatitis C, Hiv Trial in Washington, Baltimore (Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac

Active, not recruiting
  • Cardiovascular Diseases
  • +2 more
  • Elbasvir / Grazoprevir Oral Tablet [Zepatier]
  • Cardiac MRI
  • Washington, District of Columbia
  • +1 more
Feb 1, 2023

Hepatitis C Trial in Baltimore (Patient-Centered Electronic App)

Recruiting
  • Hepatitis C
  • Patient-Centered Electronic App
  • Baltimore, Maryland
    Johns Hopkins University
Mar 29, 2022

Hepatitis C Trial in Denver, Baltimore, Jackson (HCV Screening)

Enrolling by invitation
  • Hepatitis C
  • HCV Screening
  • Denver, Colorado
  • +2 more
Feb 25, 2022

Hepatitis C in HIV Infected Injection Drug Users (IDUs)

Completed
  • HIV Infection
  • Hepatitis C
    • Baltimore, Maryland
      Johns Hopkins Hospital
    Feb 17, 2022

    Renal Failure Chronic, Hepatitis C Trial in United States (glecaprevir/pibrentasvir treatment)

    Completed
    • Renal Failure Chronic
    • Hepatitis C
    • glecaprevir/pibrentasvir treatment
    • Chicago, Illinois
    • +6 more
    Jan 18, 2022

    Hepatitis C, HIV, Risk Reduction Behavior Trial in Baltimore (Peer Mentor)

    Completed
    • Hepatitis C
    • +2 more
    • Peer Mentor
    • Baltimore, Maryland
      Lighhouse Studies @ Peer Point
    Jan 19, 2022

    The HOPE Study: Characterizing Patients With Hepatitis B and C

    Recruiting
    • Hepatitis B, Chronic
    • Hepatitis C
    • Blood draws
    • +4 more
    • Washington, District of Columbia
    • +3 more
    Jan 3, 2022

    End Stage Renal Disease, Hepatitis C Trial in Baltimore (Glecaprevir/pibrentasvir)

    Active, not recruiting
    • End Stage Renal Disease
    • Hepatitis C
    • Baltimore, Maryland
      Johns Hopkins Hospital
    Dec 7, 2021

    Hepatitis C Trial in Worldwide (SOF/VEL for 6 weeks, SOF/VEL for 12 weeks)

    Completed
    • Hepatitis C
    • SOF/VEL for 6 weeks
    • SOF/VEL for 12 weeks
    • Baltimore, Maryland
    • +24 more
    Nov 22, 2021

    HIV, Hepatitis C Trial in Puerto Rico, United States (Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin

    Terminated
    • HIV Infections
    • Hepatitis C
    • Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)
    • +2 more
    • Birmingham, Alabama
    • +15 more
    Nov 2, 2021

    HIV, Hepatitis C Trial in Puerto Rico, United States (Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC))

    Completed
    • HIV Infections
    • Hepatitis C
    • Pegylated-Interferon Alfa 2b (PEG-IFN)
    • +2 more
    • Birmingham, Alabama
    • +42 more
    Nov 2, 2021

    Hepatitis C Trial in Puerto Rico, United States (ITX 5061, Placebo ITX 5061)

    Completed
    • Hepatitis C
    • ITX 5061
    • Placebo ITX 5061
    • Birmingham, Alabama
    • +9 more
    Oct 28, 2021

    HIV, Hepatitis C Trial in United States (Ribavirin, Aldesleukin, Peginterferon alfa-2b)

    Completed
    • HIV Infections
    • Hepatitis C
    • Los Angeles, California
    • +7 more
    Oct 28, 2021

    End Stage Renal Disease, Hepatitis C Trial in Baltimore (300mg glecaprevir/pibrentasivir 120mg)

    Completed
    • End Stage Renal Disease
    • Hepatitis C
    • 300mg glecaprevir/pibrentasivir 120mg
    • Baltimore, Maryland
      Johns Hopkins University
    Sep 21, 2021

    Hepatitis C, Renal Insufficiency, Chronic, Disorder of Transplanted Kidney Trial in Baltimore (Post-transplant Grazoprevir and

    Active, not recruiting
    • Hepatitis C
    • +2 more
    • Post-transplant Grazoprevir and Elbasvir
    • Baltimore, Maryland
      University of Maryland Medical Center
    Oct 5, 2021

    Hepatitis C Trial in Baltimore (Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid))

    Not yet recruiting
    • Hepatitis C
    • Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)
    • Baltimore, Maryland
      Johns Hopkins University
    Oct 6, 2021

    Direct Acting Antiviral-Post Authorization Safety Study

    Completed
    • Hepatitis C
    • Hepatocellular Carcinoma
      • Phoenix, Arizona
      • +61 more
      Jul 1, 2021

      Hepatitis C Trial in Worldwide (telaprevir, ribavirin, peginterferon alfa-2a)

      Completed
      • Hepatitis C
      • Birmingham, Alabama
      • +81 more
      Mar 3, 2021

      HIV, Hepatitis C, Cirrhosis Trial in United States (Harvoni)

      Completed
      • HIV
      • +2 more
      • San Francisco, California
      • +7 more
      Jan 12, 2021

      Hepatitis C, HIV, AIDS Trial in United States (Control Group, Care Facilitation Group)

      Completed
      • Hepatitis C
      • +3 more
      • Control Group
      • Care Facilitation Group
      • Birmingham, Alabama
      • +10 more
      Jul 21, 2020

      Hepatitis C, HCV Trial in United States (Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet)

      Completed
      • Hepatitis C
      • HCV
      • Glecaprevir/Pibrentasvir (G/P) 300mg/120mg
      • Ribavirin 200Mg Tablet
      • Palo Alto, California
      • +30 more
      Feb 17, 2020

      Subjects Who Participated inPrevious Asunaprevir and/or

      Completed
      • Hepatitis C
      • Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
      • Montgomery, Alabama
      • +160 more
      Nov 26, 2019

      Hepatitis C Trial in San Francisco, Baltimore, Albuquerque (AdCh3NSmut1, MVA-NSmut, Placebo)

      Completed
      • Hepatitis C
      • AdCh3NSmut1
      • +2 more
      • San Francisco, California
      • +4 more
      Nov 7, 2019

      Hepatitis C, Human Immunodeficiency Virus Trial in Baltimore (Maraviroc)

      Completed
      • Hepatitis C
      • Human Immunodeficiency Virus
      • Baltimore, Maryland
        Institute of Human Virology at the University of Maryland School
      Aug 15, 2019

      Hepatitis C Trial in Baltimore (Direct Acting Antivirals)

      Withdrawn
      • Hepatitis C
      • Direct Acting Antivirals
      • Baltimore, Maryland
        University of Maryland Medical Center
      Jul 1, 2019